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Background: To evaluate pancreatic tumor motion and its dynamics during respiration.
Methods and materials: This retrospective study includes 20 patients with unresectable pancreatic cancer who
were treated with stereotactic ablative radiotherapy. An online respiratory tumor tracking system was used.
Periodical maximum and minimum tumor positions with respiration in superior-inferior (SI), latero-lateral (LL), and
anterior-posterior (AP) directions were collected for tumor motion evaluation. The predictability of tumor motion in
each axis, based on reference measurement, was analyzed.
Results: The use of a 20-mm and 5-mm constant margins for SI and LL/AP directions, avoids target underdosage,
without the need for reference measurement. Pearson’s correlation coefficient indicated only a modest correlation
between reference and subsequent measurements in the SI direction (r = 0.50) and no correlation in LL (r = 0.17)
and AP (r = 0.35) directions. When margins based on the reference measurement of respiratory tumor motion
are used, then 30% of patients have a risk zone of underdosage >3 mm (in average). ITV (internal target volume)
optimization based on the reference measurement is possible, but allows only modest margin reduction (approximately
from 20 mm to 16-17 mm) in SI direction and no reduction in AP and LL directions.
Conclusion: Our results support the use of 20-mm margin in the SI direction and 5-mm margins in the LL and AP
directions to account for respiratory motion without reference measurement. Single measurement of tumor motion
allows only modest margin reduction. Further margin reduction is only possible when there is on-line tumor motion
control according to internal markers.
Keywords: Pancreatic cancer, Tumor motion, Internal target volumeBackground
Pancreatic carcinoma is a leading cause of cancer-related
mortality. Although surgery is the standard treatment of
pancreatic cancer, only 20% of patients are diagnosed with
resectable disease [1]. The outcomes after chemoradiation
for unresectable pancreatic cancer are poor, mainly be-
cause commonly used doses are not lethal for adenocarcin-
oma. The irradiated volume is correlated with significant
gastrointestinal toxicity [2]. Moreover, dose escalation is
not possible without exceeding normal tissue dose con-
straints while including regional lymph nodes [3]. The re-
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unless otherwise stated.tumor volume (GTV) plus margins to account for micro-
scopic disease (clinical target volume, CTV), tumor motion
(internal target volume, ITV) and treatment setup, (plan-
ning target volume, PTV) results in better tolerance [4-6].
The recently published American-French Consensus pro-
poses that PTV includes the GTV, with a shaped aperture
margin of 15 to 20 mm in LL and AP directions and a
margin of 20 to 30 mm in the SI direction, to take into ac-
count microscopic spreading, respiratory movements and
set-up margin [7].
Performance of four-dimensional computed tomog-
raphy (4D-CT) simulation with the creation of an ITV
might reduce the margins used to account for respiration
[8]. Controversy exists regarding whether one measure-
ment of tumor motion can predict future movement
[9,10]. Excessive volume reduction can lead to excursionsLtd. This is an Open Access article distributed under the terms of the Creative
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sage of the target. On the other hand, larger margins will
lead to unnecessary irradiation of organs at risk (OARs).
In this study we analyzed pancreatic tumor motion in
detail during a period of >3 h for each case and evalu-
ated the application of several compensatory mecha-
nisms to avoid systemic errors.
Materials and methods
This retrospective study includes 20 patients with unre-
sectable pancreatic cancer (11 women, 9 men) who were
treated between December 2011 and August 2012. We
used the CyberKnife® Robotic Radiosurgery System and
Synchrony respiratory tracking system (Accuray Inc.,
Sunnyvale, CA). Plans were designed to cover 95% of
PTV (CTV based on CT/MRI registration during re-
laxed exhale + 3-mm safety margin) with the prescribed
dose. A total of 20 tumors were treated with three frac-
tions of 10 Gy every other day. In total, 60 fractions
were analyzed. Four gold markers (fiducials) were im-
planted percutaneously under the CT control (each fi-
ducial within 30 mm from tumor center and fiducial
constellation centroid within 10 mm of the tumor cen-
ter). It is assumed that motion of the fiducial’s center
of mass (COM) closely approximates to the motion
of the tumor’s COM. Constrains for OARs were
set: 10 ml < 21Gy, 5 ml < 15Gy, 700 ml < 17Gy and
0,25 ml < 18Gy for stomach, duodenum, liver and spinal
cord respectively. Patients were asked to breathe nor-
mally during the irradiation.
Tumor motion detection
The Synchrony® Respiratory Tracking System [11] re-
cords the breathing light signal from external markers
on the chest and relates this signal to the X-ray coordi-
nates of internal markers. The system calculates model-
ling error and an adaptive algorithm is used for online
estimation of internal/external marker correlation error
during the entire session (image frequency > 1 per mi-
nute). The geometrical coordinates representing position
of the fiducials in SI, LL and AP directions in time are
extracted from the treatment X-ray images to “log” files.
This method has been proven to have high accuracy re-
garding the evaluation of tumor motion [12].
Reference measurement was calculated prior to treat-
ment (in the day of planning CT) from the correlation
model, based on the average value of tumor motion am-
plitudes within 2-5 minutes (at least 8 X-ray images to
make correlation model, 5 X-ray images for confirm-
ation of correlation model stability) or using constant
upper/lower margins from American – French consen-
sus. All CyberKnife treatments involve an initial intra-
fraction alignment step (checking the position of both
spine structures and fiducial markers), followed bycontinuous intrafraction respiratory motion monitoring
and determination [11]. According to the patient’s pre-
cise setup (spine alignment with error less than 1 mm),
no other data corrections were needed. Before each frac-
tion, the correlation model must have been created. The
analyzed data covered 95% of the total treatment time.
Over 5000 positions of COM were recorded during the
respiration cycles; approximately 800 of these, repre-
senting the maximum or minimum amplitude of tumor
motion (periodical expiration or inspiration peak), were
used for analysis.
Tumor motion analysis
To evaluate possible margins, under/overestimation of
the tumor motion based on the reference measurement,










t1 þ t2 þ…tn
Where:
TAU - the time averaged margin underestimation,
TAO - the time averaged margin overestimation,
xmargin - the margin used for ITV determination (value
from reference measurement or predefined value from
American- French consensus),
xj - the periodical tumor motion amplitude during the
j-th portion of treatment,
tj - the duration of the j-th portion of treatment
(period with stable correlation model),
t1 + t2 +…tn – the duration of the whole treatment
(n is number of correlation models),
u - the number of portions of the treatment with
underestimated margins,
o - the number of portions of the treatment with over-
estimated margins.
We used regression analysis to evaluate whether one
or more measurements of tumor motion can adequately
represent the motion of pancreatic tumors and to de-
scribe intra- and interfractional variation of tumor mo-
tion. We used linear regression function for modeling of
influence of the reference and subsequent measurements
in the SI direction. The linear function has the form
y = b0 + b1*x, where b0 equals a constant of the function
(intercept on the vertical axis), b1 equals the slope of
the linear function, x represents the first reference meas-
urement and y represents subsequent measurements
(Figure 1A). Our margin optimization uses the shift of
the linear regression line. This approach was selected
in order to lower the TAO when TAU is predefined
(the same as in the American-French approach). Our
Figure 1 Regression analysis with equations for SI (A), LL (B), and AP (C) directions. Pearson’s correlation coefficient was 0.501 (p = 0.000),
0.1719 (p = 0.0225), and 0.3461 (p = 0.000) for SI, LL, and AP, respectively. Same and similar values are overlapping. 1A: The lowest line (y =
5,8732 + 0,4064*x) is the result of regression analysis. The upper line (y = 13 + 0,4064*x) is the result of TAU and TAO optimization.
Table 1 Pancreas movement in SI direction during three
fractions, TAO and TAU for lower and upper limit for SI






Patient Max Mean Std TAU TAO TAU TAO
1 19.1 10.7 7.0 4.3 2.5 0.0 8.2
2 11.0 8.5 2.0 0.3 0.8 0.0 10.9
3 10.8 7.0 2.2 0.2 2.4 0.0 13.0
4 7.3 4.8 1.6 0.0 4.6 0.0 14.6
5 25.3 17.8 5.1 8.8 0.0 0.7 2.0
6 13.7 6.5 3.5 1.6 1.3 0.0 9.6
7 13.8 9.3 2.6 0.6 0.6 0.0 9.9
8 26.6 16.9 4.6 9.9 0.0 1.8 1.9
9 24.3 9.8 3.8 1.1 1.0 0.3 10.2
10 17.0 9.8 6.4 2.0 4.0 0.0 12.0
11 14.6 9.2 3.0 0.8 1.6 0.0 10.7
12 21.7 11.7 3.9 3.5 0.2 0.3 6.9
13 27.3 23.4 2.2 13.0 0.0 3.6 0.7
14 23.7 17.1 3.6 7.6 0.0 0.5 2.8
15 10.3 7.1 1.8 0.1 2.6 0.0 12.6
16 8.9 5.3 2.1 0.0 4.1 0.0 14.1
17 26.1 17.6 4.4 10.2 0.0 1.9 1.7
18 8.5 6.8 1.5 0.0 2.8 0.0 12.8
19 25.2 17.5 4.3 7.3 0.0 0.2 2.5
20 7.9 5.2 1.5 0.0 3.8 0.0 13.8
Mean (range) 17.2 (7.3-27.3) 11.1 (4.8-23.4) 3.6 1.6 0.5 8.5
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tumor movements caused by respiration, and enables
the setting of margins of radiation to individual patients
based on their reference measurement. The shift of the
linear regression line along the vertical axis is made
experimentally in order to find TAU nearest to the pre-
defined value. The constant part of equation (b0) is
changed by the shift, while the slope (which is defined
by the function) remains constant. TAO is calculated
from the formula afterwards.
Statistical analysis
Statistical analysis was performed using STATISTICA 10
software (Statsoft, Tulsa, OK). We used the Test for Dif-
ference Between Two Correlation or Regression Coeffi-
cients to distinguish between males and females, and the
Test for Difference Between Two Regression Coefficients
to distinguish between the slope of influence of respir-
ation amplitudes on the reference measurement.
Results
The amplitude of COM motion during respiration varied
widely among patients (range 7.3-27.3 mm in SI direc-
tion) and could vary intra-fractionally with a variation
coefficient greater than 25%, for 25% of patients; more-
over, the change of the tumor movement could be seen
unexpectedly.
Margins to account respiration without a reference
measurement
Using a margin from the upper limit (20 mm) for the SI
direction (considered in the American-French consen-
sus) resulted in low average TAU, and only one tumor
has been presented with TAU >3 mm. Unfortunately,
the use of this margin caused TAO greater than 8 mm,
on average (Table 1). When a margin from the lower
limit (10 mm) for the SI direction was used, the riskzone of TAU was >3 mm; moreover, 8 out of 20 tumors
(40%) can be missed by >3 mm (range 3.5-13 mm).
Results were different for the LL and AP directions;
the use of a margin close to the lower range of recom-
mendation (5 mm) generated low TAU and TAO. When
Table 3 Pancreas movement in AP direction during three
fractions, TAO and TAU for lower and upper limit for AP






Patient Max Mean Std TAU TAO TAU TAO
1 6.0 3.0 1.6 0.2 1.7 0.0 6.4
2 6.9 4.8 1.6 0.7 0.5 0.0 4.8
3 4.3 3.1 0.8 0.0 2.1 0.0 7.1
4 5.9 2.9 1.9 0.3 2.1 0.0 6.9
5 9.8 5.9 2.6 1.5 0.1 0.0 3.7
6 9.5 4.7 2.9 0.4 0.1 0.0 3.2
7 4.9 3.3 1.2 0.0 2.1 0.0 7.1
8 7.4 4.9 1.5 0.9 0.3 0.0 4.5
9 4.3 1.3 1.1 0.0 3.4 0.0 8.4
10 6.0 4.3 1.5 0.4 1.3 0.0 5.9
11 2.4 1.4 0.6 0.0 3.6 0.0 8.6
12 9.0 5.6 1.8 1.3 0.3 0.0 4.0
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provement of TAU was calculated, and TAO increased
unnecessarily (Tables 2 and 3).
Margins to account respiration with a reference
measurement
Pearson’s correlation coefficient indicated a modest correl-
ation in the SI direction (Figure 1A) and very poor corre-
lations in the LL and AP directions (Figure 1B, C). Given
these results, we could not hypothesize any way to predict
margins that would account for motions in the LL and AP
directions based on reference measurements.
Using margins in the SI direction based on the reference
measurement of respiratory tumor motion allowed us to
avoid overdosage, with the average geometrical miss
better than 3 mm (Table 4). However, 30% of patients
had a risk zone of underdosage that measured >3 mm
(range 3.6 – 7.4 mm)
Closer evaluation of the results clearly revealed the seg-
regation of our patients into two groups, one with move-
ment more than 15 mm, and the second with movementTable 2 Pancreas movement in LL direction during three
fractions, TAO and TAU for lower and upper limit for LL






Patient Max Mean Std TAU TAO TAU TAO
1 3.5 2.0 1.4 0.0 2.9 0.0 7.9
2 3.9 2.7 1.1 0.0 2.3 0.0 7.3
3 6.1 4.8 0.9 0.3 0.5 0.0 5.4
4 6.5 2.6 1.9 0.2 2.3 0.0 7.1
5 7.9 4.7 2.2 0.6 1.1 0.0 5.5
6 7.7 1.9 2.4 0.9 0.9 0.0 5.5
7 4.2 2.1 1.5 0.0 3.2 0.0 8.3
8 9.1 5.5 2.3 1.9 0.4 0.0 3.5
9 5.0 1.9 1.5 0.0 2.7 0.0 7.7
10 8.7 4.0 2.1 0.2 2.2 0.0 7.0
11 3.2 1.8 0.9 0.0 2.9 0.0 7.9
12 8.6 6.0 2.0 2.2 0.1 0.0 2.9
13 8.3 6.7 1.8 1.8 0.3 0.0 3.5
14 12.1 4.8 2.4 0.9 1.1 0.0 5.1
15 2.2 1.8 0.3 0.0 3.2 0.0 8.2
16 2.9 1.8 0.9 0.0 3.0 0.0 8.0
17 8.1 4.3 2.2 0.8 0.9 0.0 5.1
18 2.8 2.0 0.6 0.0 2.9 0.0 7.9
19 5.7 2.0 1.9 0.2 2.2 0.0 7.0
20 8.3 4.2 2.2 1.1 1.0 0.0 4.8
Mean (range) 6.2 (6.5-8.3) 3.4 (2.6-6.7) 0.5 1.8 0.0 6.3
13 9.5 8.2 1.2 2.8 0.0 0.0 2.2
14 7.4 4.6 1.4 0.4 0.9 0.0 5.5
15 2.8 2.2 0.4 0.0 2.7 0.0 7.7
16 3.4 0.9 0.8 0.0 4.1 0.0 9.1
17 11.9 5.6 3.0 2.7 0.4 0.5 3.2
18 3.9 2.8 0.8 0.0 2.2 0.0 7.2
19 5.9 3.8 1.2 0.3 1.0 0.0 5.7
20 3.5 2.4 0.7 0.0 2.8 0.0 7.8
Mean (range) 6.2 (5.9-9.5) 3.8 (2.9-8.2) 0.6 1.6 0.0 5.9less than 15 mm in the SI direction (Figure 1A). To keep
TAO and TAU as low as possible for patients with both
types of breathing patterns, ITV margins had to be ad-
justed accordingly: 15 mm for shallow breathing and
20 mm for deep breathing (Table 4). Similar segregation
was not observed for LL or AP directions (Figure 1B, C).
For the SI direction, we derived a “regression model”
that added an extra margin to those acquired from the
reference measurement (Figure 1A). As the results were
far from optimal (only 2-3 mm margin reduction com-
pared to a constant margin without reference measure-
ment), we evaluated patient’s variability more closely.
Women and men are known to favor different types of
breathing (chest vs. abdominal). Our results did not indi-
cate any significant difference regarding tumor motion
amplitudes (Figure 2A-C) for all three directions, while
the tumor motion prediction was higher for men, espe-
cially in the SI direction (Test for Difference Between
Two Correlation Coefficients, p = 0.0000; Test for Differ-
ence Between Two Regression Coefficients, p = 0.0001)
Table 4 Summary table of the different concepts to determine ITV in SI direction










y = 13 + 0.4064•x
Regression
analysis- man
y = 8.5 + 0.7015•x
Regression
anylysis- woman
y = 17 + 0.1804•x
TAU (mm) 3.6 0.5 2.3 0.5 0.3 0.7 0.5 0.3 0.7
TAU > 3mm (%) 40% 5% 30% 5% 0% 9% 5% 0% 9%
TAU > 1mm (%) 55% 15% 50% 20% 11% 27% 15% 11% 18%
TAO (mm) 1.6 8.5 2.7 5.6 6.2 5.1 6.7 5.6 7.4
TAO > 3mm (%) 20% 70% 25% 65% 78% 55% 85% 67% 73%
TAO > 1mm (%) 55% 95% 50% 95% 100% 91% 95% 100% 91%















Figure 2 Tumor motion amplitudes and variability of prediction for men and women. We observed no significant difference between men
and women regarding tumor motion amplitudes in all three directions: SI p = 0.056 (A); LL p = 0.549 (B); and AP p = 0.052 (C). Variability of
prediction for the SI direction (D), men: y = 2.2008 + 0.7015*x; r = 0.7285; p = 0.0000; and women: y = 9.4583 + 0.1804*x; r = 0.2695; p = 0.0163. Test
for difference between two correlation coefficients, p = 0.0000. Test for difference between two regression coefficients, p = 0.0001. LL direction
(E), men: y = 1.7543 + 0.4717*x; r = 0.4572; p = 0.000; and women: y = 4.6229-0.2843*x; r = -0.2505; p = 0.026. Test for difference between two
correlation coefficients, p = 0.0000. Test for difference between two regression coefficients, p = 0.0001. AP direction (F), men: y = 1.8117 + 0.346*x;
r = 0.4538; p = 0.0000; and women: y = 2.7144 + 0.261*x; r = 0.1993; p = 0.0802. Test for difference between two correlation coefficients, p = 0.07.
Test for difference between two regression coefficients, p = 0.57.
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reduction (1 mm) was seen.
Correlation between internal and external markers during
respiration
To get correlation error less than 3 mm (median
1.53 mm, range 0.01-3.09 mm), we had to establish more
than 3 correlation models per treatment (median 9.5
times, range 4-18) whenever we observed a correlation
error between internal and external markers greater than
3 mm. The median duration of one model was 19 min
(range 1-87 min). 10 out of 20 patients (50%) were pre-
sented with low stability between internal and external
markers and more than 9 models had to been done per
treatment (3 fractions).
Discussion
The treatment response of pancreatic tumors to radio-
therapy treatment remains poor. Given the strong radio-
resistance of adenocarcinomas, dose escalation is needed
but it is not possible without margin reduction [3-6].
In the present study, tumor motion was greatest in the
SI direction, in agreement with data from other institu-
tions [2,9,10,13,14]. According to our measurements (20patients, monitoring time 4676 min), the mean respiration
amplitude between inhalation and exhalation was 11 mm
(range 5-23 mm), which appears to be comparable to pre-
viously published results from larger studies. Bussels et al.
obtained their data by using dynamic MRI to quantify
pancreatic motion in 12 patients; instead of placing fidu-
cials, they acquired one image every second for 1 min.
They observed a larger degree of movement in the SI dir-
ection: 24 mm ±16 mm [15,16] compared to our result
(1 minute of monitoring seems to be short and MRI
tumor detection could be less precise). Although smaller
tumor motion amplitudes have also been presented, those
studies are based on a much smaller number of measure-
ments [10,13,14]. Murphy et al. reported the results of
only one patient imaged fluoroscopically for 1 min; the pa-
tient had three gold fiducials sutured into the tumor, and
the maximal SI movement was 6 mm with breathing (13).
Gierga et al. published a study of six patients who also
underwent invasive marker placement and were observed
fluoroscopically for 30 sec. The range of average SI mo-
tions was 4.4–12 mm (14). Hallman et al. concluded that
the mean COM motion for pancreatic tumors was 5 mm
(standard deviation 1 mm), with a range of 3 to 7 mm
(10). We observed mean tumor motion of approximately
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LL and AP directions respectively, which supports the rec-
ommendation for asymmetrical margins as published by
Goldstein et al. [9].
To the best of our knowledge, this is the first study to
quantify under- or overestimation of tumor motion during
a longer time period. With the use of TAO and TAU, we
were able to derive margins for the optimization of under-
dosage and overdosage. Our analysis clearly shows the
feasibility of the concept of larger margin (20 mm) consid-
ered by the American-French consensus [7] for the SI dir-
ection, and lower (5 mm) for the LL and AP directions to
account respiration. The use of smaller margins in the SI
direction would cause an average underdosage zone of ap-
proximately 3 mm; moreover, 40% of patients would have
an average geometrical miss of >3 mm. Abdominal com-
pression might be useful [17] to minimize tumor motion,
especially for the 50% of patients that presented with an
average tumor motion of >15 mm. Limitations of our
study could be using the tumor tracking system to simu-
late reference measurement instead of 4DCT and short
time of monitoring (3 fractions in 1 week compared to
5 weeks of fractionated radiotherapy).
Planning 4D-CT is commonly used to customize the
internal margin in patients with abdominal tumors [8].
Our results show that the motion of pancreatic tumors
is modestly predictable with respiration in the SI direc-
tion (correlation coefficient r = 0.50) and unpredictable
in the LL (r = 0.17) and AP (r = 0.35) directions when de-
rived from the reference measurement. Margins based
on the reference measurement of tumor motion avoid
overdosage with an average geometrical miss of <3 mm
in our group. However, 30% of patients have a risk zone
of underdosage >3 mm caused by inter-/intrafractional
changes of breathing pattern, that seems unacceptable.
When Minn et al. [18] compared the planning of 4D-CT
motion with intrafractional motion measured in a
single-fraction respiratory tracking radiotherapy; they
found that the geometrical miss could exceed 10% for 16
out of 20 patients. Compared with our results, they
found an additional modest correlation for the AP direc-
tion. However, only the average value from all conse-
quential measurement points was used, compared to our
approach assessing the correlation between reference
and subsequent measurements [18]. In a study of four
pancreatic tumors monitored during 38 fractions, Ge
et al. concluded that the motion measured with 4D-CT
did not adequately represent actual motion during radi-
ation therapy. The 4D-CT disagreed with 95% of the
fractions, 55% of which were underestimated and 40% of
which were overestimated [19]. Cai et al. found that
gated internal volume based on 4D-CT could underesti-
mate tumor motion in respiratory-gated therapy, mainly
because of breathing variability [20]. James et al. foundthat the instability of internal target volume varied from
46% to 127% [21].
Our results are not in compliance with recommenda-
tions for the use of 4D-CT [9,10]. Goldstein et al. ob-
served that the volumes and excursions were relatively
unchanged during the treatment course, obviating the
need for re-planning during treatment [9]. However, the
monitoring time was short, only two measurements were
taken for 50% of patients, and inter-/intrafractional vari-
ability may have remained hidden; the duration of few
breaths could not represent the entire treatment time.
Hallman et al. recommend using respiratory gating to-
wards the end of exhalation, which might substantially
reduce the range of motion. They found an average shift
of 5 mm (range 3-7 mm) for SI direction [10]. Abdom-
inal motion was determined by one respiratory cycle,
which could be a limitation of this study.
We have derived two methods of ITV optimization
based on the reference measurement. Our algorithms
allow us to reduce the margin (approximately from
20 mm to 17 mm for women and from 20 mm to 16 mm
for men) in the SI direction, compared with the use of
constant margins without reference measurement. No
additional risk of underdosage was found. Our preliminary
results showed much better prediction capability for men
than for women, resulting in a smaller ITV and lower risk
of overdosage for men. The amplitude analysis has not
shown any significant difference between men and women
(Figure 2A-C). Even after detailed analysis, the predict-
ability of movement in both the LL and AP directions
remains poor. Moreover, we have detected occasional
unpredictable COM shifts caused by intestinal and duo-
denal peristalsis; therefore, another extra margin might
be added.
Finally, we had to create approximately 200 correlation
models with median duration of 19 min (range 1-
87 min) to obtain good correlation between tumor mo-
tion and skin markers (error smaller than 3 mm). This
finding is in agreement with the results of Feng et al.,
who demonstrated poor correlation between the tumor
position and the abdominal wall and diaphragm. Poor
reproducibility in breathing pattern has also been shown
[16]. These additional uncertainties should be accounted
for when image guidance with external markers (without
fiducials) is used.
Conclusion
Our results support the use of a 20-mm margin in the
SI direction and a 5-mm margin in the LL and AP direc-
tions to account respiratory motion without a reference
measurement. ITV optimization, based on the reference
measurement, allows a small margin reduction in the SI
direction (approximately from 20 mm to 16-17 mm) and
no margin reduction in the LL/AP directions, with no
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use of constant margins. Further margin reduction is
only possible when there is on-line tumor motion con-
trol according to internal markers.
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